Uganda’s locally made sickle cell drug faces a rural access test

More than 1,780 patients are registered for long-term sickle cell care at Lira Regional Referral Hospital in Uganda. Health officials believe others remain undiagnosed, especially in rural communities. That gap forms the backdrop to a local pharmaceutical push: Quality Chemical Industries Limited, or Qcil, says it has launched Ugandan-made hydroxyurea, a medicine that helps control the disease’s complications, according to The Independent Uganda (direct).

The company’s announcement puts domestic drug production alongside a wider challenge for Uganda’s health system: getting people tested and keeping treatment within reach. Hydroxyurea is used to reduce the frequency and severity of complications, including painful crises. It does not cure sickle cell disease, an inherited condition that requires long-term management. For patients, the issue is therefore not only diagnosis, but access to continuing care.

Local production, wider ambitions

Rohit Datar, Qcil’s head of business development and private market, said local manufacturing would make the medicine more available and affordable, while cutting Uganda’s dependence on imported supplies. He described the launch as a way to strengthen the country’s pharmaceutical independence. The source did not provide production volumes, prices or a measure of how much costs would fall.

Datar said locally manufactured hydroxyurea would widen treatment access, lower costs and reduce Uganda’s reliance on imported medicines.

The production push was highlighted around the Lango Regional Sickle Cell Stakeholders Summit 2026 in Lira. The two-day meeting brought together Ministry of Health officials, healthcare professionals, implementing partners, cultural and religious leaders, and other community stakeholders. Their agenda extended beyond medicine supply to prevention, early testing, diagnosis, treatment and long-term care. Participants called for stronger regional leadership, better public understanding and improved access to treatment.

Datar said limited knowledge of sickle cell disease was contributing to misconceptions and late diagnosis in some communities. He said Qcil had joined other participants in encouraging early testing and appropriate medical care, while challenging the stigma attached to the condition. The emphasis on awareness placed community outreach alongside pharmaceutical production in the regional response: having a medicine available is one part of the effort, while identifying patients is another.

Bringing treatment closer

The Ministry of Health is planning a gradual expansion of hydroxyurea access through lower-level health facilities. The aim is to move treatment closer to patients, particularly rural residents who must travel long distances for specialised care. That planned shift would extend access beyond the specialist services on which such patients currently depend.

Lira’s registered patient count gives one indication of the demand for continuing care, but health officials caution that it may not capture the full burden. People who have not been diagnosed, particularly outside urban centres, remain a concern. The summit’s focus on testing and awareness reflects that uncertainty, alongside the needs of patients already receiving treatment.

The next developments to watch are the ministry’s planned expansion into lower-level facilities and whether Qcil’s domestic production delivers the improvements in availability and affordability that Datar described. Together, those efforts target the supply and distance barriers identified in the regional response.